2 weeks Ago By ABMN Staff
Russell Investments Group Ltd. lifted its stake in shares of Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ) by 28.
0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,890 shares of the life sciences company’s stock after purchasing an additional 23,788 shares during the period. Russell Investments Group Ltd.
owned approximately 0.14% of Integra LifeSciences worth $2,470,000 at the end of the most recent quarter. Other hedge funds have also modified their holdings of the company.
Arrowstreet Capital Limited Partnership raised its stake in Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after purchasing an additional 913 shares during the period.
Nisa Investment Advisors LLC grew its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares in the last quarter.
Villanova Investment Management Co LLC lifted its stake in Integra LifeSciences by 10.8% in the 4th quarter. Villanova Investment Management Co LLC now owns 43,224 shares of the life sciences company’s stock worth $980,000 after acquiring an additional 4,217 shares in the last quarter.
PNC Financial Services Group Inc. lifted its stake in Integra LifeSciences by 33.6% in the 4th quarter.
PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock worth $448,000 after acquiring an additional 4,967 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Integra LifeSciences by 4.
1% in the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock valued at $2,919,000 after purchasing an additional 5,032 shares during the period. 84.
78% of the stock is owned by hedge funds and other institutional investors. Integra LifeSciences Trading Up 0.5 % Integra LifeSciences stock opened at $15.
83 on Friday. Integra LifeSciences Holdings Co. has a one year low of $15.
46 and a one year high of $32.66. The company’s fifty day moving average price is $21.
30 and its two-hundred day moving average price is $22.22. The company has a market capitalization of $1.
22 billion, a price-to-earnings ratio of -175.87, a PEG ratio of 0.73 and a beta of 1.
24. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.
20 and a quick ratio of 0.73. Analysts Set New Price Targets IART has been the topic of several research reports.
Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, April 11th.
Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.
71. Check Out Our Latest Stock Analysis on Integra LifeSciences Integra LifeSciences Profile ( Free Report ) Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies.
The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. See Also Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
